BC
CERO

Birchview Capital’s CERo Therapeutics CERO Stock Holding History

Birchview Capital’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6
Closed -$778 – 71
2024
Q4 		$778 Hold
6
– – ﹤0.01% 68
2024
Q3 		$1.21K Hold
6
– – ﹤0.01% 61
2024
Q2 		$3.88K Hold
6
– – ﹤0.01% 60
2024
Q1 		$39.8K Buy
+6
New +$67.1K 0.03% 58

Other funds holding CERO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Birchview Capital's CERO Position: Q1 2025 in Review

Birchview Capital sold out of CERo Therapeutics (CERO) in Q1 2025, closing a stake of 6 shares — an estimated $778 sold.

Birchview Capital first reported a position in CERO in Q1 2024 and held it in 4 quarters. The position peaked at $39.8K in Q1 2024. 13 funds tracked by Wall St. Rank hold CERO as of Q1 2025.

  • Birchview Capital reported no remaining CERo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Birchview Capital sold 6 CERo Therapeutics shares in Q1 2025, an estimated $778.
  • Birchview Capital first reported a position in CERo Therapeutics in Q1 2024 and held it in 4 quarters.
  • Birchview Capital's CERo Therapeutics position peaked at $39.8K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2025.

Based on Birchview Capital's 13F filing for Q1 2025, filed 15 May 2025.